ProstaLund
ProstaLund signs distribution agreement for Italy
ProstaLund AB has signed an exclusive distribution agreement with the Italian company DISTRIBUZIONE BIOMEDICALI ITALIA, DBI srl. The agreement is expected to generate revenues of at least SEK 1.5 million during the first two years of the agreement period.
Earlier this year, ProstaLund began internationalization outside the Nordic region and has signed distribution agreements for, among others, the UK and Spain in Europe. The next step in this process is now being taken when a distribution agreement for ProstaLund's Schelin Catheter and CoreFlow – Soft Stent has been signed for Italy with Distribuzione Biomedicali Italia, DBI srl.
DBI is already the exclusive distributor throughout Italy for Boston Scientific's product lines in urology, including the equipment, water vapor and green laser, to treat benign prostatic hyperplasia. With the help of ProstaLund's products, DBI's existing customers can now be offered a holistic concept that means that the treatments can be performed under local anesthesia and thereby save resources.
During the fall, ProstaLund introduced the Schelin Catheter and CoreFlow – Soft Stent at a handful of clinics in Italy with very good results. The partnership with DBI enables the introduction to be significantly accelerated.
"After the initial very good results, we have been actively looking for a partner in Italy to be able to address the market faster. The collaboration with DBI is probably as close to a perfect marriage as you can get.", says CEO Johan Wennerholm in a comment.
Datum | 2022-12-27, kl 17:10 |
Källa | MFN |
